Clinical Challenges

Gemcitabine-Associated Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome

Jeanne Held-Warmkessel

gemcitabine, renal injury, thrombocytopenia, TTP, HUS
ONF 2014, 41(5), 551-553. DOI: 10.1188/14.ONF.551-553

A patient being treated for metastatic adenocarcinoma of the pancreas presents to the clinic for a routine appointment. A complete blood count reveals hemoglobin of 6.5 g/dl and a platelet count of 30,000 K/mm3 thought to be from the last of many doses of gemcitabine. On assessment, the only complaint was fatigue with no evidence of bleeding or other abnormal physical findings other than pallor. Past medical history includes hypertension managed with three antihypertensive agents. Additional laboratory tests reveal elevated blood urea nitrogen (69 mg/dl), creatinine (2.76 mg/dl), and lactic dehydrogenase (LDH), was well as indirect bilirubin (2.1 mg/dl). The patient is admitted and transfused with packed red blood cells (pRBCs). The next day, the platelet count drops to 9,000 K/mm3 and the hemoglobin increases, appropriately, to 8.9 g/dl. Urinalysis is positive for hemoglobin (+ 3). The peripheral blood smear is positive for schistocytes (fragmented RBCs). A pheresis catheter is placed after the patient was evaluated by a hematologist and a nephrologist. A presumptive diagnosis of thrombotic thrombocytopenic purpura (TTP) with hemolytic uremic syndrome (HUS) was made.

Jump to a section


    Blackall, D. P., & Marques, M. B. (2004). Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation. American Journal of Clinical Pathology, 121(Suppl.), S81-S88. doi:10.1007/s00467-008-0935-6.
    Cohen, J. A., Brecher, M. E., & Bandarenko, N. (1998). Cellular source of lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 13, 16-19.
    Furlan, M., & Lammle, B. (2001). Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: The role of von Willebrand factor-cleaving protease. Best Practice in Research Clinical Haematology, 14, 437-454. doi:10:1053/beha.2001.0142
    George, J. N. (2006). Clinical practice thrombotic thrombocytopenic purpura. New England Journal of Medicine, 354, 1927-1935. doi:10.1056/NEJMcp053024
    George, J. N. (2010). How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood, 116, 4060-4069. doi:10.1182/blood-2010-07-27-1445
    George, J. N. (2013). Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults. Retrieved from
    Gore, E. M., Jones, B. S., & Marques, M. B. (2009). Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? Journal of Clinical Apheresis, 24, 209-214. doi:10.10002/JCA20213
    Hovinga, J. A. K., Studt, J. D., Alberio, L., & Lammle, B. (2004). Von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: The Swiss experience. Seminars in Hematology, 41, 75-82.
    Humphreys, B. D., Sharman, J. P., Henderson, J. M., Clark, J. W., Marks, P. W., Rennke, H. G., … Magee, C. C. (2004). Gemcitabine-associated thrombotic microangiopathy. Cancer, 100, 2664-2670.
    Izzedine, H., Isnard-Bagnis, C., Launary-Vacher, V., Mercadal, L., Tostivint, I., Rixe, O., … Deray, G. (2006). Gemcitabine-induced thrombotic microangiopathy: A systemic review. Nephrology Dialysis Transplant, 21, 3038-3045.
    Kaplan, A. A., & George, J. N. (2013). Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults. Retrieved from
    Moake, J. L. (2002). Thrombotic microangiopathies. New England Journal of Medicine, 347, 589-600. doi:10.1056/NEJMra020528
    Myers, L. (2002). Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Pathophysiology and management. Nephrology Nursing Journal, 29, 171-180.
    Tsai, H. M. (2013). Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. American Journal of Medicine, 126, 200-209. doi:10.1016/j.amjmed.2012.09.006
    Tun, N. M., & Villani, G. M. (2012). Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: A systematic review with pooled data analysis. Journal of Thrombosis and Thrombolysis, 34, 347-359. doi:10.1007/S11239-012-0723-9
    Zupancic, M., Shah, P. C., & Shah-Khan, F. (2007). Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncology, 8, 634-641.